BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hybridon, Inc. (HYBN) To Present At Biotechnology Industry Organization (BIO) CEO And Investor Conference


10/19/2005 5:12:48 PM

CAMBRIDGE, Mass., Feb. 22 /PRNewswire-FirstCall/ -- Hybridon, Inc. announced today that Sudhir Agrawal, D. Phil, Hybridon's President, Chief Executive Officer, and Chief Scientific Officer, will present an overview of the Company's discovery and drug development programs at the 2005 BIO CEO and Investor Conference. The presentation will take place at 3:30 PM at the Waldorf-Astoria in New York on Thursday, February 24, 2005.

The presentation can be accessed via a live webcast on the webcasts page of Hybridon's website: http://www.hybridon.com/webcasts.php

An archived version of the webcast will be available two hours after the live webcast, and remain active through Saturday, March 19th, 2005, on Hybridon's website and the BIO CEO website.

About Hybridon

Hybridon, Inc. is developing novel therapeutics based on synthetic nucleic acids for the treatment of cancer, asthma/allergies, and infectious diseases. Hybridon's proprietary drug candidates are designed to modulate immune responses through Toll-like receptor 9. The Company's nucleic acid chemistry expertise has generated a broad portfolio of intellectual property, partnered products and licenses, creating long-term value for Hybridon. For more information please visit our website at http://www.hybridon.com/.

Contacts: Hybridon, Inc. Euro RSCG Life NRP 617-679-5500, x 5517 212-845-4268 Robert G. Andersen Robert Stanislaro (media) E-mail: randersen@hybridon.com 212-845-4269 Brian Ritchie (investors

Hybridon, Inc.

CONTACT: Robert G. Andersen of Hybridon, Inc., +1-617-679-5500, x 5517,randersen@hybridon.com; or Robert Stanislaro (media), +1-212-845-4268, orBrian Ritchie (investors), +1-212-845-4269, both of Euro RSCG Life NRP, forHybridon, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES